Literature DB >> 19635949

Efficacy of albaconazole against Candida albicans in a vaginitis model.

Gloria M González1, Efrén Robledo, Elvira Garza-González, Mariana Elizondo, J Gerardo González.   

Abstract

The efficacy of albaconazole (ABC) was evaluated using a murine model of vaginal Candida albicans infection. Both ABC and fluconazole (FLC) were effective in reducing the fungal load from vaginas of infected mice; however, ABC demonstrated encouraging activities against an FLC-resistant strain, with trends toward superiority over FLC in some treatment groups.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19635949      PMCID： PMC2764185          DOI： 10.1128/AAC.00565-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  In vitro activities of 10 antifungal drugs against 508 dermatophyte strains.

Authors:  B Fernández-Torres; A J Carrillo; E Martín; A Del Palacio; M K Moore; A Valverde; M Serrano; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

2.  Treatment of vaginal candidosis--a UK patient survey 1989.

Authors:  P J Tooley
Journal:  Br J Clin Pract Suppl       Date:  1990-09

3.  In vitro antiproliferative effects and mechanism of action of the new triazole derivative UR-9825 against the protozoan parasite Trypanosoma (Schizotrypanum) cruzi.

Authors:  J A Urbina; R Lira; G Visbal; J Bartrolí
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi.

Authors:  J Capilla; M Ortoneda; F J Pastor; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

5.  In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.

Authors:  G Ramos; M Cuenca-Estrella; A Monzón; J L Rodríguez-Tudela
Journal:  J Antimicrob Chemother       Date:  1999-08       Impact factor: 5.790

6.  Genetic susceptibility to vaginal candidiasis.

Authors:  L Calderon; R Williams; M Martinez; K V Clemons; D A Stevens
Journal:  Med Mycol       Date:  2003-04       Impact factor: 4.076

7.  Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. Comparison and pilot study.

Authors:  M B Slavin; G I Benrubi; R Parker; C R Griffin; M J Magee
Journal:  J Fla Med Assoc       Date:  1992-10

Review 8.  Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush).

Authors:  M Nurbhai; J Grimshaw; M Watson; Cm Bond; J Mollison; A Ludbrook
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

9.  In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

Authors:  J L Miller; W A Schell; E A Wills; D L Toffaletti; M Boyce; D K Benjamin; J Bartroli; J R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

10.  In vitro susceptibilities of Malassezia species to a new triazole, albaconazole (UR-9825), and other antifungal compounds.

Authors:  Margarita Garau; Manolo Pereiro; Amalia del Palacio
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.